StonvexLoading…
StonvexStonvexStonvexCore line items from XRAY's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $3.68B | $3.79B | $3.96B | $3.92B |
Operating Income | $-422.00M | $-879.00M | $-85.00M | $-937.00M |
Net Income | $-598.00M | $-910.00M | $-132.00M | $-950.00M |
EPS (Diluted) | $-3.00 | $-4.48 | $-0.62 | $-4.41 |
Total Assets | $5.43B | $5.75B | $7.37B | $7.64B |
Total Liabilities | $4.09B | $3.81B | $4.08B | $3.83B |
Cash & Equivalents | $326.00M | $272.00M | $334.00M | $365.00M |
Free Cash Flow OCF − CapEx | $104.00M | $281.00M | $228.00M | $368.00M |
Shares Outstanding | 199.60M | 198.80M | 207.20M | 215.20M |